History

Juniper Pharmaceuticals (Nasdaq: JNP) has a successful track record of developing women’s health therapeutics.

Having developed and brought to market six products, each commercialized through strategic alliances, we are excited to resume a proprietary product development program.

Timeline

1986 Columbia Laboratories incorporated as a Delaware Corporation
1988 IPO on the American Stock Exchange (COB)
1997 Crinone® (progesterone gel) approved by FDA
1997 U.K.-based pharmaceutical services provider Molecular Profiles founded
2004 Began trading on the Nasdaq stock exchange (CBRX)
2004 Sold three OTC bioadhesive women’s healthcare products to Church & Dwight
May 2010 Renewed license and supply agreement with Merck KGaA, Darmstadt, Germany, for Crinone® in all foreign markets.
Jul 2010 Sold U.S. rights to Crinone® to Allergan for $62 million, a 10% royalty on future sales, and potential milestones related to the achievement of certain regulatory milestones.
Apr 2013 License and supply agreement with Merck KGaA, Darmstadt, Germany, for Crinone® for all foreign markets amended and extended through 2020.
Sep 2013 Acquired Molecular Profiles, now Juniper Pharma Services
Mar 2015 Acquired exclusive worldwide license to a segmented intravaginal ring (IVR) technology developed by Dr. Robert Langer at the Massachusetts Institute of Technology and Dr. William Crowley at Massachusetts General Hospital and Harvard Medical School.
Apr 2015 Rebranded as Juniper Pharmaceuticals (Nasdaq: JNP) and Juniper Pharma Services.
Nov 2015 Announced three IVR product candidates
July 2016 Crinone® approved in Japan under OneCrinone® brand
Aug 2016 Discontinued development of COL-1077 following Phase 2b study results
Nov 2016 Monetized U.S. Crinone® royalty with Allergan, providing $11M in non-dilutive cash to Juniper
Sep 2017 Strategic reprioritization to focus on growth in core businesses of Crinone® and Juniper Pharma Services and focus research & development efforts on JNP-0201 for hormone replacement therapy